2 Biological Activity
JNJ-38877605 is an orally bioavailable, highly specific MET inhibitor (selective over other 229 kinases tested). This agent inhibits c-MET and Phospho-MET with IC50 at 4 nmol/L and 50 nmol/L, respectively. In addition, JNJ-38877605 induces regression of U87-MG xenografts in vivo. [1]
3 References:
Drug development of MET inhibitors: targeting oncogene addiction and expedience Paolo M. Comoglio, Silvia Giordano,et al. Drug Discovery June2008;7:504-516
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.
![2 Biological Activity
JNJ-38877605 is an orally bioavailable, highly specific MET inhibitor (selective over other 229 kinases tested). This agent inhibits c-MET and Phospho-MET with IC50 at 4 nmol/L and 50 nmol/L, respectively. In addition, JNJ-38877605 induces regression of U87-MG xenografts in vivo. [1]
3 References:
Drug development of MET inhibitors: targeting oncogene addiction and expedience Paolo M. Comoglio, Silvia Giordano,et al. Drug Discovery June2008;7:504-516
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.](http://uc-hk2.njagan.com/oss/enogene-backend-image/E1KS1114/img/435.png)
